At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
cetuximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Sep 3, 2007·Updated Mar 12, 2020
In Brief
A Phase 2 clinical trial evaluating cetuximab for Head and Neck Cancer and Precancerous Condition. Completed, enrolled 35 participants across 10 sites in 2 countries.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block abnormal cell growth in different ways. Some block the ability of abnormal cells to grow and spread. Others find abnormal cells and help kill them or carry cell-killing substances to them. PURPOSE: This randomized phase II trial is studying how well cetuximab works in treating patients with precancerous lesions of the upper aerodigestive tract.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer, Precancerous Condition
CountriesCanada, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedSep 2007
Primary CompletionDec 2011
TodayJul 2026
First PostedSep 3, 2007
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.8 years ago
Interventions
cetuximabbiological
given IV